GlassScriptPhysician profile
Fahed Sabagh
NPI 1932421179
$2,875.93
in general payments reported to CMS, 2019-2025
15 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $122 · 2021: $461 · 2022: $225 · 2023: $731 · 2024: $254 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $953.64 | 2019-2024 | Injectafer |
| Aimmune Therapeutics, INC. | $249.29 | 2025 | Zenpep |
| Pharmacosmos Therapeutics INC. | $230.64 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.20 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.76 | 2024 | Caplyta |
| Pfizer INC. | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $120.00 | 2019 | |
| Alkermes, INC. | $119.98 | 2023 | Lybalvi |
| Edwards Lifesciences Corporation | $118.42 | 2019 | |
| Sobi, INC | $117.18 | 2023 | |
| Axsome Therapeutics, INC. | $110.88 | 2025 | Auvelity |
| Amag Pharmaceuticals, INC. | $107.84 | 2021 | |
| Amgen INC. | $93.10 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahed Sabagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.